These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM; Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Vosslamber S; Raterman HG; van der Pouw Kraan TC; Schreurs MW; von Blomberg BM; Nurmohamed MT; Lems WF; Dijkmans BA; Voskuyl AE; Verweij CL Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302 [TBL] [Abstract][Full Text] [Related]
24. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA; Pincus T Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
25. Pediatric systemic lupus erythematosus in Thammasat University Hospital. Pusongchai T; Jungthirapanich J; Khositseth S J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427 [TBL] [Abstract][Full Text] [Related]
26. In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al. van Vollenhoven R; Gunnarsson I Arthritis Rheum; 2005 Dec; 52(12):4050-1; author reply 4051-2. PubMed ID: 16320358 [No Abstract] [Full Text] [Related]
33. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Haug-Rost I; Braun J; Sieper J Ann Rheum Dis; 2013 Feb; 72(2):305-6. PubMed ID: 22887847 [No Abstract] [Full Text] [Related]
34. Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: a case report. Bienaimé F; Quartier P; Dragon-Durey MA; Frémeaux-Bacchi V; Bader-Meunier B; Patey N; Salomon R; Noël LH Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1346-50. PubMed ID: 20191570 [No Abstract] [Full Text] [Related]
36. CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al. Kamburova EG; Koenen HJ; Joosten I; Hilbrands LB Arthritis Rheum; 2013 Apr; 65(4):1130-1. PubMed ID: 23335076 [No Abstract] [Full Text] [Related]
37. Colitis associated with active systemic lupus erythematosus successfully treated with rituximab. Tayal V; Chiu YH; George E; Mane S J Clin Rheumatol; 2011 Mar; 17(2):79-82. PubMed ID: 21325960 [TBL] [Abstract][Full Text] [Related]
38. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965 [TBL] [Abstract][Full Text] [Related]